Good news for busy healthcare professionals: MedShorts 360 brings the month's most useful medical developments together in one place. Read new evidence on medicines available in India, highlights from every major specialty, India's pharma news, results from the world's leading conferences and the stories that matter to patients. Every update is short, clear and linked to its original source.
No updates match. Clear the search, or bookmark stories to see them under Bookmarked.
New evidence on medicines your patients can get in India, across the major specialties.
CardiologyA registry-based randomised trial found default prasugrel did not cut death, MI or stroke at one year versus ticagrelor in acute coronary syndrome patients undergoing PCI.
Infectious DiseasesA JAMA synopsis of the IDSA guideline backs 5-7 day courses for non-bacteraemic cUTI, 7 days for Gram-negative bacteraemia, and advises against nitrofurantoin for complicated infection.
SurgeryA review of 16 studies presented at ANESTHESIOLOGY 2026 linked perioperative melatonin to over 30% less opioid use in some abdominal surgery, and zolpidem to less pain.
DiabetesThe REMODEL MRI trial missed its main imaging endpoints, but semaglutide lowered renal resistive index, albuminuria and kidney fat in people with type 2 diabetes and CKD.
CardiologyIn the COHERENT trial, colchicine 0.5 mg daily cut hsCRP by about 40% over six months, yet pulse wave velocity did not change and office systolic pressure fell less than with placebo.
GastroenterologyIn over 2,400 propensity-matched US adults with difficult asthma, long-term proton pump inhibitor use was tied to more exacerbations, rescue steroids and respiratory infections.
GynaecologyIn a US cohort of more than 300 pregnancies, higher stress went with lower vitamin C intake and fussier babies, and supplemental vitamin C appeared to mediate part of that link.
SurgeryIn over two million US surgical patients, GLP-1 drug users had 11% lower odds of major cardiovascular complications and 8% lower odds of postoperative infection.
OncologyASCO's 2026 update ties adjuvant abemaciclib or ribociclib to estimated 10-year breast cancer mortality, and prefers abemaciclib when a patient qualifies for both.
Infectious DiseasesIn a Swedish birth cohort of 2,853 people, antibiotic use from age 9 was linked to higher odds of IBS at 24, rising with the number of courses, especially for cephalosporins.
GynaecologyAn Australian population study of 177,409 children found antenatal metformin exposure was not associated with developmental vulnerability at school entry after adjustment.
OrthopaedicsA three-arm randomised trial in Radiology found ultrasound-guided saline hydrodissection kept improving symptoms at six months, while steroid-only patients relapsed.
PsychiatryAcross 19 observational studies with nearly 16 million people, ADHD was associated with 70% higher all-cause mortality, and medication use with about 25% lower risk.
NeurologyUS records of 21,923 people with epilepsy showed 32.6% had at least two weeks of overlap between a contraceptive and an antiseizure drug, a combination that can reduce contraceptive effect.
DermatologyAcross 50 studies with 4,403 patients, antiepileptics caused about 23% of SJS/TEN cases, led by carbamazepine, with a higher share in children.
OrthopaedicsIn 20 patients followed for 30 months, polidocanol plus autologous marrow cut pain scores from 6.2 to 0.3 and cyst volume from about 80 mL to 2 mL, with 5% recurrence.
DiabetesPooling 85 double-blind trials with over 70,000 adults, SGLT2 inhibitors raised haemoglobin by 0.6 g/dL and haematocrit by 2.4 percentage points, with a small rise in erythropoietin.
DermatologyEris Lifesciences has launched DCGI-approved tapinarof 1% cream, a once-daily aryl hydrocarbon receptor agonist, citing phase 3 PSOARING data on clearance and itch.
GastroenterologyIn a matched retrospective cohort, ulcerative colitis patients on liraglutide or semaglutide had 12-week symptomatic remission of 66.7% versus 25.3% in non-users, independent of weight loss.
DiabetesA once-daily pill combining sitagliptin 50 mg, metformin 1000 mg and glimepiride 1 mg lowered HbA1c by 1.79% at 16 weeks, versus 1.27% with free metformin and glimepiride.
NeurologyIn the ClearMEMory trial, two-thirds of SLE patients on memantine improved by at least 8 points on a cognition battery over 12 weeks, versus 36% on placebo.
Infectious DiseasesIn a randomised cancer-centre trial presented at IDWeek 2026, stopping empirical antibiotics before count recovery did not raise death, septic shock or ICU transfer, and nearly tripled antibiotic-free days.
OrthopaedicsAmong 228 patients, beginning a biologic within two years of diagnosis gave the same short-term DAPSA response as starting later, leaving long-term joint protection unanswered.
NeurologyA BRIDGE-TNK analysis at the World Stroke Congress found cardioembolic strokes benefited from tenecteplase before thrombectomy, but large-artery atherosclerotic strokes did not.
DermatologyIn an Italian retrospective series of 26 women, 0.25% topical finasteride for a year raised hair density, shaft thickness and terminal-to-vellus ratio, with no reported side effects.
PsychiatryPharmacovigilance and Japanese claims data suggest aripiprazole carries lower hyponatraemia risk than olanzapine, with brexpiprazole and lurasidone also reporting fewer cases.
CardiologyLight transmission aggregometry at AIIMS New Delhi showed aspirin resistance in 30.5% and clopidogrel resistance in 36.8% of 151 patients with stable coronary artery disease.
SurgeryA PGIMER Chandigarh randomised trial found faster extubation, higher peak flow and a smaller FEV1 drop with sugammadex 2 mg/kg than with neostigmine-glycopyrrolate.
PsychiatryA regional analysis presented at ECNP 2026 found opposite associations between folic acid dispensing and suicide-related deaths in men aged 20-24 and 25-29, and none in women.
OncologyIn 1,249 Chinese patients with diabetes who had liver resection for hepatocellular carcinoma, starting a GLP-1 receptor agonist was linked to 42% lower mortality than starting a DPP-4 inhibitor.
OncologyA prospective Indian otolaryngology study found 65 of 90 cisplatin-treated patients developed irreversible bilateral sensorineural hearing loss, and urged routine audiometry.
GastroenterologyPooling 30 randomised trials, fibre supplements raised the chance of clinical response in IBS by 21%, and psyllium by about 53%, while wheat bran gave no benefit.
GynaecologyAmong 624,713 first births in Sweden, women vaccinated against HPV before pregnancy had lower odds of preterm birth, PPROM and severely small babies, especially if vaccinated before 17.
A key development from each specialty, from hepatology to palliative care.
Sleep MedicineIn an NYU randomised trial of 196 short sleepers with prediabetes, each hour of earlier sleep onset was associated with about 0.6 kg more weight loss over eight weeks.
Geriatric MedicineThe eSTEPS cluster-randomised trial in 22 US practices cut fall rates by 9% using electronic alerts that prompted personalised home balance and strength programmes.
Clinical ImmunologyA French double-blind trial of 98 patients found similar remission duration with six-monthly rituximab or daily azathioprine, but twice the rate of severe infections with rituximab.
Critical CareThe VASSPR cluster crossover trial found 28-day mortality of 31.8% with an early vasopressin threshold versus 33.0% with a later one.
EndocrinologyAmong 90 patients at a New Delhi tertiary centre, 35.6% had asymptomatic disease, surgery cured all operated patients, and cinacalcet normalised calcium in 90%.
HepatologyStudies in The Lancet and Nature Medicine found SOMAscan, MR elastography and FibroScan-based scores most accurate for advanced fibrosis, and GGT better than FIB-4 as a first screen.
Infectious DiseasesSequencing saliva and sputum from 771 UK patients six months after hospital discharge showed microbiome differences in those with the most severe long COVID.
Preventive and Lifestyle MedicineIn a 16-week single-arm trial, eating a low-fat plant-based diet without calorie counting reduced weight by 6 kg, liver fat by 33% and HbA1c by 1 percentage point.
Emergency MedicineIn 75 stable PSVT patients at AIIMS New Delhi, the modified Valsalva restored sinus rhythm in 26.3% at one minute versus 16.2% with the standard manoeuvre, a difference that was not significant.
PulmonologyA North Indian prospective study of 50 AECOPD admissions found steroid duration was the only independent predictor of a stay over nine days.
Tropical MedicineThe price cut is expected to save about $50 million from 2027 to 2029 and allow up to one million more children to receive the full four-dose course.
DiabetologyIn a placebo-controlled trial in North Indian adults with prediabetes, metformin 500 mg twice daily for 24 weeks lengthened telomeres and raised telomerase and SIRT1 activity.
Allergy and AsthmaBelgian real-world data on more than 280,000 patients linked short-acting bronchodilator use to higher mortality, especially three or more inhalers a year.
RheumatologyIn the Chinese TACTIC trial of 116 patients, leflunomide 20 mg plus prednisone gave 81.5% remission at 24 weeks versus 78.9% with placebo plus prednisone.
Pain MedicineIn 194 patients treated in Berlin, median knee pain fell from 7 to 3 on a 10-point scale and stayed there at 12 months after embolisation with resorbable microspheres.
Medical OncologyIn 303 patients from seven US and Australian centres, 48% developed chronic immune-related adverse events, and 34% still had them at last follow-up.
Palliative MedicineThe EQUAL ACP trial in 791 seriously ill older adults found no significant difference in planning completion between facilitated and self-guided approaches within Black or White participants.
Nuclear MedicineIn the Italian FUPERMAN study, PSMA PET/CT-targeted biopsy detected clinically significant cancer in 37% of men with negative or equivocal MRI, versus 21% with systematic biopsy.
HaematologyA Swedish prospective study found M protein in one in four adults hospitalised with invasive pneumococcal disease, and new blood cancers or precursor conditions in 19 of 156.
Approvals, pricing, policy and business news from India's pharmaceutical sector.
PricingA 2 November order under DPCO 2013 sets retail prices for cardiovascular, antidiabetic, anticancer, anti-infective, GI and analgesic formulations from companies including Sun, Cipla, Mankind and Dr Reddy's.
BusinessThe contract research and manufacturing company reported Q2 FY27 revenue of Rs 833 crore and a profit of Rs 32 crore, after a loss in Q1.
ExportsThe generic of Pfizer's Depo-Medrol in single- and multi-dose vials addresses a US market of about $214 million a year.
HIV preventionDr Reddy's is the first of six Gilead licensees to get tentative approval for the twice-yearly HIV prevention injection, at an expected price of about $40 a year.
ExportsLupin's amifampridine 10 mg tablets, a generic of Catalyst's Firdapse used in Lambert-Eaton myasthenic syndrome, qualify for shared first-to-file exclusivity in the US.
LegalThe court told NPPA not to take coercive steps until 11 January 2027 over alleged overcharging on Symbicort Turbuhaler 160/4.5 under DPCO 2013.
BusinessRevenue reached Rs 969 crore and profit Rs 73 crore. Zaynich, approved in the US and India for complicated UTI, is in the pre-launch phase.
BusinessThe CDMO reported Q2 FY27 revenue of Rs 1,342 crore and profit of Rs 115 crore, and is entering colour cosmetics manufacturing through a Rs 56 crore acquisition.
PolicyPrivate hospitals are challenging a state circular requiring itemised bills to show procurement cost, MRP and the amount charged for medicines and consumables from 1 November.
ExportsThe generic of Climara Pro, made at Zydus's Moraiya plant near Ahmedabad, is a Competitive Generic Therapy eligible for 180-day exclusivity.
RegulatoryReviewing Novo Nordisk's application for oral semaglutide 1.5-25 mg for weight management, the committee asked for Indian bioequivalence data and justification of absorption-enhancer levels.
Oncology approvalsThe anti-PD-1 antibody, combined with cisplatin and paclitaxel, is approved first-line without PD-L1 testing, citing a median overall survival of 17.7 versus 12.9 months in JUPITER-06.
BusinessThe two-tranche issue, with coupons of 8.05% and 8.20%, will replace a dollar bridge loan taken for the Organon deal, Reuters reported.
OncologyNCCN has listed UNLOXCYT as a Category 2A preferred option for locally advanced cutaneous squamous cell carcinoma when curative surgery or radiation is not possible, Sun Pharma says.
RegulatoryThe oncology expert committee recommended the new presentation for preventing skeletal events in bone metastases, subject to post-marketing surveillance and a PKU label warning.
PolicyThe 6 October guidelines allow only factual, verifiable information and bar fake reviews, paid rankings, guaranteed outcomes and AI-generated testimonials.
Late-breaking results from major international meetings.
TCT 2026, San DiegoThe VERITAS study of 458 patients reported 99.3% implant success, 96.3% complete closure and 1.8% stroke or systemic embolism at one year.
TCT 2026, San DiegoIn the SIRONA trial, freedom from repeat target-lesion procedures was 88.2% with the MagicTouch sirolimus balloon versus 80.2% with paclitaxel balloons.
TCT 2026, San DiegoPascal T-TEER beat medical therapy on a six-month win ratio driven by health status, with 80% of patients at moderate or less regurgitation at one year.
Kidney Week 2026, DenverIn 4,633 adults with chronic kidney disease, aspirin did not significantly reduce major vascular events and caused more major bleeding.
Kidney Week 2026, DenverPovetacicept, atacicept and sibeprenlimab, which all target the APRIL/BAFF pathway, sharply reduced proteinuria or preserved eGFR in late-breaking trials.
IDWeek 2026, Washington DCIDWeek data included oral olorofim matching AmBisome in aspergillosis, aztreonam-avibactam staying active against rising MBL-producing bacteria, and five days of oseltamivir prophylaxis matching ten.
ESMO 2026, MadridDeLLphi-305 showed median overall survival of 21.1 versus 12.7 months when the DLL3-targeted T-cell engager was added to first-line maintenance.
ESMO 2026, MadridIn the Chinese HARMONi-GI1 trial, the PD-1/VEGF bispecific antibody improved median overall survival to 14.9 versus 12.1 months.
ESMO 2026, MadridThe SAFFRON trial extended progression-free survival to 7.6 versus 5.4 months, and overall survival to 17.8 versus 12.9 months, in EGFR-mutant lung cancer with MET overexpression or amplification.
ESMO 2026, MadridIn the VOLGA trial, the perioperative doublet cut the risk of events by 49% and death by 42%, with a pathological complete response of 45% versus 10%.
ESMO 2026, MadridIn the phase 3 DASL-HiCaP trial of 1,106 men, four-year metastasis-free survival was 95% with darolutamide versus 88% with placebo.
ESMO 2026, MadridINTerpath-001 showed 24-month recurrence-free survival of 82.2% with the individualised neoantigen therapy plus pembrolizumab, versus 70.0% with pembrolizumab alone.
HFSA 2026, PhoenixIn 2,684 matched US patients, acoramidis was linked to an 18% lower risk of a composite of death, hospitalisation, new AF or diuretic intensification.
CHEST 2026, PhoenixPooled phase 3 OBERON and TITANIA data showed 30% fewer moderate or severe exacerbations and 27% fewer severe ones, with benefits across eosinophil levels.
Health news from India that affects patients and their care.
Patient safetyA 15-day statewide operation by health and police teams inspected clinics across districts, with most cases in Rajkot and Surat.
Maternal healthMysuru's C-section share rose from 43.7% to 47.4% between survey rounds, with the increase mainly at public facilities.
Patient safetyRejecting a police closure report, the court asked a Crime Branch SIT to investigate complications after multiple procedures at a facility registered only as a day-care centre.
Addiction careUnion Health Minister JP Nadda launched capacity building for doctors, nurses, counsellors and community health workers, coordinated by NDDTC, AIIMS New Delhi.
Digital healthNine servers at Kamalnayan Bajaj Hospital were encrypted, delaying medicines, claims and government scheme benefits, and an FIR has been filed.
Patient safetyThe cell, set up after a Gauhati High Court PIL, registered 115 FIRs, including cases of forged credentials used inside hospitals.
Health workforceThe state is verifying the status of 695 government doctors appointed since 1988, as vacant posts leave rural patients without care.
Hospital costsIn an affidavit, the Centre acknowledged mark-ups on medicines and consumables from 100% to over 1,000%, but said it lacks the data to regulate hospital margins.
Medicine accessA health department circular requires stock lists for OPD doctors, generic prescribing and fortnightly reagent reports to avoid treatment disruptions.
International health news that matters to patients.
Global healthWHO's mid-term review of the 2021-2030 NTD road map finds 36% fewer people needing interventions than in 2010, but most targets off track as external funding shrinks.
Food safetyWHO's updated estimates covering 42 hazards in 194 countries show children under five bear a disproportionate share, mostly from diarrhoeal disease.
FertilityIn an NEJM trial of 737 couples, one IVF cycle gave a 55% live birth rate versus 31% with up to four IUI cycles, though long-term success was similar.
OutbreaksOver 10,000 confirmed cases have been reported in DR Congo, with spread to Kenya and Nigeria, and the US will bar recent DRC travellers from boarding flights from 3 November.
HypertensionAn analysis of nine trials with 91,339 patients found those who took at least 80% of doses had 11% fewer major cardiovascular events, while poor adherers had no significant benefit.
Child dental healthIn a US phase 3 trial of 830 children under six, twice-yearly SDF application stopped decay in more than half of affected baby teeth, without drilling or injections.
Drug safetyAn AI analysis of about 150,000 Reddit posts found users of gray-market retatrutide often reported increased appetite, sleep problems and a racing heart, unlike in clinical trials.
Weight-loss drugsAn EADV 2026 study across four countries found nail detachment in 39% of GLP-1 users versus 9% of comparable non-users, and more hair thinning.
Rare diseaseThe FDA has approved Zanvastro, an antisense therapy that lowers the toxic GFAP protein, after a 54-patient trial showed faster walking and stabilised motor function.
MedShorts 360 summaries are written by the MedShorts editorial team from the cited sources, for registered healthcare professionals. They are not medical advice. Please read the original source before applying findings in practice.
Sponsor a specialty stream or a conference desk, delivered to doctors, pharmacists and field teams in one consistent, compliant format.